PATENT CLAIM ANALYSIS

Application Number: 16027029
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["548", "400000"]

Abstract:
Provided herein are Mcl-1 antagonist compositions and methods of treating cancer using the compositions described herein.

Claim (Index 95):
The method of  claim 94 , wherein:\n R 4  is R 11 -substituted or unsubstituted alkyl or R 11 -substituted or unsubstituted aryl, wherein R 11  is halogen, oxo, \u2014OH, substituted or unsubstituted alkyl or substituted or unsubstituted aryl; R 2  is hydrogen, joined together with R 1  to form a substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl, or joined together with R 3  to form substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted aryl; and R 3  is hydrogen.

Metadata:
- Claim Count in Document: 245.0
- Percentile: 95.0
- Lexical Diversity: 1.13333
- Patent Class: 548.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15123232', '15662861', '15700040', '15214282', '15421258']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8204125062796503
- 35 USC 102 Novelty (BERT): 0.6573564656390836
- Combined Prediction Score: 0.8041069022155938
- Mean Citation Score: 615.5831919999998
- Max Citation Score: 733.3489
- Similarity Product: 585.8153993687449

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test